Secretases as targets for the treatment of Alzheimer's disease: The prospects

Lancet Neurology

Volumn 1, Issue 7, 2002, Pages 409-416

  Dewachter, Ilse ^a   Van Leuven, Fred ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; L 685458; NOTCH RECEPTOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; ENZYME INHIBITOR; PROTEINASE; SECRETASE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; DISEASE COURSE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; ANIMAL; BIOSYNTHESIS; CELL MEMBRANE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; CELL MEMBRANE; ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; SIGNAL TRANSDUCTION;

EID: 0042630561     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00188-6     Document Type: Review

References (47)

1. Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschr Pschiatrie Psych-gericht. Med Berlin. 64:1907;146-148.
2. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 120:1984;885-890.
3. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 12:1997;558-559.
4. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;23-31.
5. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a b-sheet breaker peptide. FASEB J. 16:2002;860-862.
6. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
7. Terwel D, Dewachter I, Van Leuven F. Axonal transport, protein tau and neurodegeneration in Alzheimer's disease, NeuroMol Med (in press).
8. Meziane H., Dodart J.C., Mathis C., et al. Memory-enhancing effects of secreted forms of the amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA. 95:1998;12683-12688.
9. Mattson M.P. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77:1997;1081-1132.
10. Buxbaum J.D., Liu K.N., Luo Y., et al. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 273:1998;27765-27767.
11. Lammich S., Kojro E., Postina R., et al. Constitutive and regulated a-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA. 96:1999;3922-3927.
12. Roghani M., Becherer J.D., Moss M.L., et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem. 274:1999;3531-3540.
13. Anders A., Gilbert S., Garten W., Postina R., Fahrenholz F. Regulation of the α-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 15:2001;1837-1839.
14. Esler W.P., Wolfe M.S. A portrait of Alzheimer secretases: new features and familiar faces. Science. 293:2001;1449-1454.
15. Schlöndorff J., Becherer J.D., Blobel C.P. Intracellular maturation of the tumor necrosis factor α convertase (TACE). Biochem J. 347:2000;131-138.
16. Rio C., Buxbaum J.D., Peschon J.J., Corfas G. Tumor necrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem. 275:2000;10379-10387.
17. Mechtersheimer S., Gutwein P., Agmon-Levin N., et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol. 155:2001;661-673.
18. Vincent B., Paitel E., Saftig P., et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem. 276:2001;37743-37746.
19. Dewachter I., Reverse D., Caluwaerts N., et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci. 22:2002;3445-3453.
20. Vassar R., Bennett B.D., Babu-Khan S., et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic proteinase BACE. Science. 286:1999;735-741.
21. Howlett D.R., Simmons D.L., Dingwall C., Christie G. In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci. 23:2000;565-570.
22. Cai H., Wang Y., McCarthy D., et al. BACE1 is the major β-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 4:2001;233-234.
23. Hong L., Koelsch G., Lin X., et al. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science. 290:2000;150-153.
24. Kitazume S., Tachida Y., Oka R., Shirotani K., Saido T.C., Hashimoto Y. Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA. 98:2001;13554-13559.
25. Luo Y., Bolon B., Kahn S., et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci. 4:2001;231-232.
26. Brown M.S., Ye J., Rawson R.B., Goldstein J.L. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 100:2000;391-398.
27. De Strooper B., Saftig P., Crassaerts K., et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 391:1998;387-390.
28. Sisodia S.S., St George-Hyslop P.H. γ-secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 3:2002;281-290.
29. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 89:1997;629-639.
30. Wong P.C., Zheng H., Chen H., et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 387:1997;288-292.
31. Schneider I., Reverse D., Dewachter I., et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem. 276:2001;11539-11544.
32. Yu G., Nishimura M., Arawaka S., et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and bAPP processing. Nature. 407:2000;48-54.
33. Li Y.M., Xu M., Lai M.T., et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:2000;689-694.
34. Steiner H., Kostka M., Romig H., et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol. 2:2000;848-851.
35. Sambamurti K., Greig N.H., Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. NeuroMol Med. 1:2002;1-31.
36. Ebinu J.O., Yankner B.A. A RIP tide in neuronal signal transduction. Neuron. 34:2002;499-502.
37. Cao X., Sudhof T.C. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 293:2001;115-120.
38. Kimberly W.T., Zheng J.B., Guenette S.Y., Selkoe D.J. The intracellular domain of the β-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem. 276:2001;40288-40292.
39. Wolfe M.S., Xia W., Moore C.L., et al. Peptidomimetic probes and molecular modeling suggest that Alzheimer's γ-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry. 38:1999;4720-4727.
40. Shearman M.S., Beher D., Clarke E.E., et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry. 39:2000;8698-8704.
41. Petit A., Dumanchin-Njock C., Andrau D., Da Costa C.A., Checler F. Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat Cell Biol. 5:2002;111-112.
42. Dovey H.F., John V., Anderson J.P., et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem. 76:2001;173-181.
43. Feng R., Rampon C., Tang Y.P., et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 32:2001;911-926.
44. Yu H., Saura C.A., Choi S.Y., et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 31:2001;713-726.
45. Van Dorpe J., Smeijers L., Dewachter I., et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol. 157:2000;1283-1298.
46. Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 276:2001;47863-47868.
47. Dewachter I., Van Dorpe J., Smeijers L., et al. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci. 20:2000;6452-6558.